One-Year Insights into the GLOBOSTAD Multinational Prospective Observational Study of Patients Receiving Dupilumab for Atopic Dermatitis

Atopic Dermatitis

Decreased Risk of Reduced Linear Growth Among Children with Atopic Dermatitis Receiving Dupilumab: A Cohort Study

J Am Acad Dermatol

Chen TL, Ma SH, Ou WF, Chen CC, Wu CY

doi: 10.1016/j.jaad.2025.08.020

Atopic Dermatitis

Psoriasis Risk in Patients With Atopic Dermatitis Treated With Dupilumab

JAMA Dermatol

Lin TL, Fan YH, Fan KS, Juan CK, Chen YJ, Wu CY

doi: 10.1001/jamadermatol.2025.1578

Melanoma and Skin Cancer

Enhanced overall and progression-free survival in advanced melanoma patients undergoing targeted therapy alongside antithrombotic treatment - Insights from a multicenter study involving 1296 patients from the prospective skin cancer registry ADOReg

Eur J Cancer

Zimmermann N, Kött J, Zell T, Abedini AZ, Blomen CL, Belz S, Deitert B, Heidrich I, Geidel G, Rünger A, Smit DJ, Weichenthal M, Ugurel S, Leiter U, Berking C, Gutzmer R, Schadendorf D, von Wasielewski I, Mohr P, Meier F, Herbst R, Utikal J, Terheyden P, Haferkamp S, Pföhler C, Kaatz M, Ziller F, Ulrich J, Meiss F, Bauer AT, Schneider SW, Gebhardt C

doi: 10.1016/j.ejca.2025.116195

Atopic Dermatitis

Dupilumab treatment in children aged 6 months to 5 years with severe atopic dermatitis

J Eur Acad Dermatol Venereol

Lasek A, Bellon N, Mallet S, Aubert H, Vera C, Achour L, Thénié C, Prescilla R, Abasq-Thomas C, Barbarot S

doi: 10.1111/jdv.70268

Atopic Dermatitis

Safety and efficacy of nemolizumab for atopic dermatitis up to 2 years in open-label extension study

J Eur Acad Dermatol Venereol

Augustin M, Tauber M, Sidbury R, Silverberg JI, Papp KA, Thaçi D, De Bruin-Weller MS, Reich A, Peris K, Barber K, Galus R, Kaszuba A, Zirwas M, Nahm WK, Trullenque G, Maintz L, Alpizar S, Son SW, Laquer V, Gold LS, Cheong SY, Ryzhkova A, Drahos A, Ulianov L, Piketty C

doi: 10.1111/jdv.70080

Atopic Dermatitis

The real-world, long-term risk of infections associated with dupilumab in atopic dermatitis: A global cohort study

J Eur Acad Dermatol Venereol

Kridin K, Abdelghaffar M, Bieber K, Thaci D, Ludwig RJ

doi: 10.1111/jdv.20724

Acne

Safe and Effective Acne Treatment Across Skin Types with a 1726 nm Sebum-Selective Laser: One Year Data from a Prospective Multicenter Study

J Am Acad Dermatol

Goldberg D, Ronan S, Bhatia A, Dhawan SS, Green JB, Kilmer SL, Kwan W, Stein Gold L, Weiss JS, Doucette M, Karavitis M, Dover JS

doi: 10.1016/j.jaad.2025.09.077

Atopic Dermatitis

Successful Dose Reduction of Janus-kinase Inhibitors in Well-controlled Atopic Dermatitis: A Prospective, Multicentre, Real-world Study

Acta Derm Venereol

Schlösser AR, Caron AGM, Den Ouden MS, Baart SJ, Gerbens LAA, Spuls PI, Nijsten TEC, Schappin R, Hijnen D

doi: 10.2340/actadv.v105.44165

Atopic Dermatitis

Efficacy and safety of lebrikizumab in adult and adolescent patients with moderate-to-severe atopic dermatitis inadequately controlled with or ineligible for ciclosporin A: a placebo-controlled, randomized phase IIIb clinical study (ADvantage)

Br J Dermatol

Warren RB, de Bruin-Weller M, Tsianakas A, Khemis A, Szepietowski JC, Hong HC, Mihaylov Y, Falqués M, Agell H, Massana E, Gil EG, Coll R, Weidinger S

doi: 10.1093/bjd/ljaf285

Related content

Decreased Risk of Reduced Linear Growth Among Children with Atopic Dermatitis Receiving Dupilumab: A Cohort Study

Psoriasis Risk in Patients With Atopic Dermatitis Treated With Dupilumab

Enhanced overall and progression-free survival in advanced melanoma patients undergoing targeted therapy alongside antithrombotic treatment - Insights from a multicenter study involving 1296 patients from the prospective skin cancer registry ADOReg

Dupilumab treatment in children aged 6 months to 5 years with severe atopic dermatitis

Safety and efficacy of nemolizumab for atopic dermatitis up to 2 years in open-label extension study

The real-world, long-term risk of infections associated with dupilumab in atopic dermatitis: A global cohort study

Safe and Effective Acne Treatment Across Skin Types with a 1726 nm Sebum-Selective Laser: One Year Data from a Prospective Multicenter Study

Successful Dose Reduction of Janus-kinase Inhibitors in Well-controlled Atopic Dermatitis: A Prospective, Multicentre, Real-world Study

Efficacy and safety of lebrikizumab in adult and adolescent patients with moderate-to-severe atopic dermatitis inadequately controlled with or ineligible for ciclosporin A: a placebo-controlled, randomized phase IIIb clinical study (ADvantage)